Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

03 mai 2018 07h30 HE | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Reports First Quarter 2018 Financial Results and Business Updates

WALTHAM, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
26 avr. 2018 08h30 HE | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Report First Quarter 2018 Financial Results and Business Updates on May 3, 2018

WALTHAM, Mass., April 26, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
09 avr. 2018 08h30 HE | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder

WALTHAM, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
15 mars 2018 08h30 HE | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Host Key Opinion Leader Meeting on the Negative Symptoms of Schizophrenia on Thursday, March 22

WALTHAM, Mass., March 15, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a biopharmaceutical company focused on the development of therapies to treat central nervous system...
12 mars 2018 07h30 HE | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates

Four late-stage trials underway, targeting schizophrenia, major depressive disorder and insomnia disorder Planning for commercialization moves forward Management to host conference call today at...
05 mars 2018 08h30 HE | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Report Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2018

WALTHAM, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
05 févr. 2018 08h30 HE | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Names Remy Luthringer as Executive Chairman and William Doyle as Lead Independent Director

WALTHAM, Mass., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS)...
21 déc. 2017 08h00 HE | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant (MIN-202) Versus Quetiapine as Adjunctive Therapy to Antidepressants in Patients With Major Depressive Disorder

WALTHAM, Mass., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
19 déc. 2017 08h00 HE | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Screens First Patient in Phase 3 Trial Of MIN-101 to Treat Negative Symptoms in Schizophrenia

Multi-center, international trial targets significant unmet need for which no treatments are approved Approximately 500 patients to be enrolled at 60 clinical sites in U.S. and Europe WALTHAM,...
11 déc. 2017 16h30 HE | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Names Richard Russell President

WALTHAM, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...

Page précédente